. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: J Androl. 2010 Aug 26;32(1):40–48. doi: 10.2164/jandrol.110.010983

Table 1.

Baseline comparison

Variable	Placebo (n=16)	Treatment (n=17)	P - value
Age (year)	69.0 (2.2) ^*	69.2(2.5) ^*	0.94
Race—White/Black (n)	11/5	15/2
Weight (Kg)	97.39 (4.73)^*	90.20 (4.01)^*	0.25
BMI (Kg/m²)	30.05 (1.44)^*	28.71 (1.24)^*	0.48
PSA (ng/ml)	45.05 (39.54)^*	3.90 (2.58)^*	0.30
TSH (mIU/ml)	1.98 (0.22)^*	1.81 (0.24)^*	0.60
Duration of ADT to baseline (year)	1.96 (0.64) ^*	2.37 (0.37) ^*	0.70
GnRH Analogues/Orchiectomy (n)	16/0	16/1
AR Antagonist (n)	1	3
Radiation Therapy (n)	11	13
History of Metastases (n)	7	7
Number of abnormalities in system review	3.19 (0.42) ^*	3.41 (0.52) ^*	0.74

Mean (standard error)